New Hampshire Medicaid spending on GLP-1 drugs

How much did New Hampshire Medicaid spend on GLP-1 drugs like Ozempic and Mounjaro in 2025?

Pharmacies were reimbursed at least $37.5 million for GLP-1 drugs paid through New Hampshire Medicaid in 2025, across at least 34,652 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 67 rows of 190, so these figures are floors.

Pharmacies were reimbursed at least $3.9 million for GLP-1 drugs paid through New Hampshire Medicaid in 2026 (quarter 1 only, as posted so far), across at least 3,913 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 18 rows of 45, so these figures are floors.

By year and ingredient

2020at least $374,359No dataat least $2,175,655at least $956,190at least $684,249SuppressedSuppressedat least $4,190,453
2021at least $749,626No dataat least $3,708,883at least $1,645,138at least $569,436SuppressedNo dataat least $6,673,083
2022at least $1,594,913at least $8,511at least $4,780,590at least $3,966,953at least $422,183SuppressedNo dataat least $10,773,150
2023at least $5,476,720at least $408,146at least $3,670,607at least $6,342,778at least $195,668SuppressedSuppressedat least $16,093,919
2024at least $14,717,713at least $2,714,727at least $1,122,498at least $3,971,106at least $46,183No dataSuppressedat least $22,572,228
2025at least $24,683,784at least $9,148,134at least $485,921at least $3,169,225SuppressedNo dataSuppressedat least $37,487,064
2026 (Q1)at least $2,147,377at least $1,098,363at least $10,575at least $601,532No dataNo dataSuppressedat least $3,857,847

By product, 2025

Ozempicat least $8,088,521at least 8,30111 of 23
Rybelsusat least $242,251at least 2302 of 12
Wegovyat least $16,353,012at least 12,96113 of 33
Mounjaroat least $2,738,650at least 2,8474 of 28
Zepboundat least $6,409,484at least 6,45511 of 35
Liraglutide (generic name listing)at least $165,444at least 36111 of 23
Saxenda$311,4252810 of 4
Victozaat least $9,051at least 137 of 8
Trulicityat least $3,169,225at least 3,2032 of 18
BydureonSuppressedSuppressed2 of 2
XultophySuppressedSuppressed4 of 4

By quarter, 2025

Q1 2025at least $8,467,024at least 7,93913 of 46
Q2 2025at least $9,256,118at least 8,50420 of 51
Q3 2025at least $9,882,377at least 9,03618 of 48
Q4 2025at least $9,881,545at least 9,17316 of 45

By quarter, 2026 (posted so far)

Q1 2026at least $3,857,847at least 3,91318 of 45

The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:

“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”

Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”

CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.

Fee-for-service and managed care rows are added together. Other states: Medicare and Medicaid spending on GLP-1 drugs.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.